Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA yield is N/A as of 2026-10-06T18:05:35.770Z.
Calculation as of: 2026-10-06T18:05:35.770Z.
Quote observation: 2026-10-06T18:00:04.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 8c4e2329810c85a761ec37603feeca28f75a2d8b2781946fcb814d6340a505d6
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EBITDA YIELD
N/A
Market Cap
$7.13M
EBITDA Yield
N/A
TTM Avg
372.43%
3Y Avg
151.61%
5Y Avg
151.61%
| NAME | MARKET CAP | EBITDA YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Skye Bioscience, Inc. (SKYE) | $7.29M | N/A | N/A | N/A | N/A |
| InMed Pharmaceuticals Inc. (INM)vs › | $7.25M | N/A | N/A | N/A | N/A |
| Longeveron Inc. (LGVN)vs › | $7.21M | N/A | N/A | N/A | N/A |
| Mangoceuticals, Inc. (MGRX)vs › | $7.13M | N/A | N/A | N/A | N/A |
| NeuroSense Therapeutics Ltd. (NRSN)vs › | $6.95M | N/A | N/A | N/A | N/A |
| Exicure, Inc. (XCUR)vs › | $6.95M | N/A | N/A | N/A | N/A |
| KALA BIO, Inc. (KALA)vs › | $7.07M | N/A | N/A | N/A | N/A |
| Co-Diagnostics, Inc. (CODX)vs › | $7.13M | N/A | 372.43% | 151.61% | 151.61% |
| Bolt Biotherapeutics, Inc. (BOLT)vs › | $6.94M | N/A | N/A | N/A | N/A |
| Curanex Pharmaceuticals Inc Common Stock (CURX)vs › | $6.84M | N/A | N/A | N/A | N/A |
EBITDA Yield = TTM EBITDA / Enterprise Value
EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
